The FDA's fast track designation aims to expedite ITM-94's development for diagnosing clear cell renal cell carcinoma. The ...
MedPage Today on MSN
Better Survival in Kidney Cancer After Stopping Therapy for Immune-Related AEs
D ENVER -- Patients who discontinued treatment for advanced kidney cancer because of immune-related adverse events (irAEs) ...
DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...
TKI-based regimens remain the primary approach for metastatic renal cell carcinoma after immune checkpoint inhibitor therapy, ...
Researchers examined the association between BMI trajectory and outcomes in RCC, finding worse OS in patients who lost weight after diagnosis.
ITM-94 forms a theranostic pair with therapeutic candidate ITM-91, targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma ...
Limited data exist on outcomes in mRCC patients with major venous involvement (MVI). Assessment of impact of a given variable on prognosis in cancer patients is challenging given competing causes of ...
Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer PURPOSE: Sarcomatoid ...
Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback